IMPORTANCE Although β-blockers are a mainstay of treatment after acute myocardial infarction (AMI), these medications are commonly not prescribed for older nursing home residents after AMI, in part owing to concerns about potential functional harms and uncertainty of benefit.
It is particularly important for the 1.4 million Americans who reside in nursing homes, who are at high risk for functional decline and often strongly value preserving whatever remaining functional independence they have. 19, 20 In this study, we evaluated the effect of β-blockers on functional outcomes in older nursing home residents with AMI and compared these functional outcomes with the effect of β-blockers on death and rehospitalization in this population.
Methods

Data Sources and Participants
We obtained data from Medicare Part A and Part D (prescription drug benefit) claims; the Online Survey Certification and Reporting System (OSCAR), which provides facility-level information on nursing home characteristics, staffing, and quality indicators; and the Minimum Data Set (MDS), version 2.0, which consists of assessments of nearly all nursing home residents in the United States. Minimum Data Set assessments occur a minimum of every 3 months, and more often for patients with a major recent change in clinical status and those receiving care under the Medicare Skilled Nursing Facility benefit. This study was approved by the institutional review boards of the University of California, San Francisco, and the Department of Veterans Affairs, who waived the need for informed consent.
Our study population consisted of US nursing home residents 65 years or older who were hospitalized for AMI from May 1, 2007 , to March 31, 2010 ; had resided in a nursing home for at least 30 days before the AMI hospitalization; had not used a β-blocker for at least 4 months before hospitalization; and returned to a nursing home after hospital discharge 21 (eAppendix 1 in the Supplement provides additional details). We defined hospitalization with AMI based on a hospital admission or discharge claim with code 410.XX or 411.1 from the In- 
Measures
Our exposure of interest was use of a β-blocker in the immediate posthospital period. We defined this as a Part D claim for an oral β-blocker within 30 days of resuming Part D coverage after hospital discharge. Part D covers at least 81% of nursing home residents and in most cases is the sole source of prescription drug coverage for these patients. 24 For the subset of patients who return to the nursing home under the Medicare Skilled Nursing Facility benefit, resumption of Part D claims is temporarily delayed. Therefore, we conducted a companion validation study to evaluate the performance of our β-blocker exposure measure in this subset. This study confirmed the validity of our measure (eAppendix 1 in the Supplement). Our primary outcome was functional decline. We defined this as a loss of 3 points on the validated Morris scale of independence in ADLs between the prehospital baseline assessment and the first available assessment after hospitalization, to 3 months after discharge.
23 A 3-point drop corresponds to a major loss of independence in 1 ADL or incremental losses in 2 or more ADLs. In a sensitivity analysis, we evaluated the outcome as a 4-point (more substantial) decline in function. We chose a 90-day outcome period because it is long enough to be clinically meaningful but short enough that many of these highly vulnerable patients have not yet died, a competing outcome that complicates interpretation of longerterm functional outcomes.
Other key outcome measures included death and rehospitalization within 90 days of the index hospital discharge. We used data from Medicare Part A and Medicare enrollment files to identify hospital admissions and date of death. We also explored the following 2 composite outcomes: time to hospitalization or death, and time to hospitalization, death, or functional decline.
Information on chronic conditions and characteristics of the index hospitalization were obtained from Medicare Part A data. Overall, this data source is more accurate for identifying chronic conditions than MDS 2.0. [25] [26] [27] [28] The MDS 2.0 provided data on other patient characteristics, including functional and cognitive status, geriatric syndromes, and symptoms, including validated scales such as the Cognitive Performance Score and CHESS scores. 22, 29 We used the OSCAR data set to evaluate a variety of nursing home facility characteristics such as staffing, resident mix, and quality indicators.
Statistical Analysis
We used propensity score-based methods to evaluate the association between β-blocker exposure and our outcomes of interest. Following an intention-to-treat framework, we defined participants as β-blocker users or nonusers throughout the study period based on their exposure in the immediate post-AMI period.
We estimated the propensity score via a logistic regression model that used 93 variables to predict β-blocker use. Variables included sociodemographic characteristics, chronic medical conditions, baseline medication use, hospitalization history, baseline functional and cognitive status, geriatric syndromes, symptoms, characteristics of the AMI hospitalization, and nursing home characteristics (eAppendix 2 in the Supplement). To evaluate whether vital signs, laboratory test results, and measures of cardiac function could result in unmeasured confounding, we conducted a companion validation study using national data from the Department of Veterans Affairs, which, unlike Medicare claims data, contains information on these variables. We found no evidence that the absence of these factors would substantially alter our results (eAppendix 3 in the Supplement).
To match β-blocker users with nonusers who had similar propensity scores, we first discarded participants in the top and bottom 1% of the propensity score distribution so as to exclude areas of nonoverlap. We then applied a 1:1 greedy 5-to-1 digit-matching algorithm without replacement. 30 We evaluated the quality of resulting matches by comparing standardized differences between groups for each covariate in our model and by using 2-tailed t tests to assess differences in the distribution of propensity scores. 31, 32 Our propensity matching yielded an excellent covariate balance, so we did not further adjust for baseline covariates in our models. Because we excluded people who died or were rehospitalized during the first 14 days after hospital discharge, we did not consider outcomes that occurred during this period, thus effectively beginning our outcome analyses at day 14 after hospitalization.
We used Cox proportional hazards regression models to determine the effect of β-blocker use on time to death. We used the method of Fine and Gray (similar to Cox regression) to evaluate the effect of β-blocker use on time to rehospitalization while accounting for the competing outcome of death. 33 Finally, we used multinomial logit models to evaluate the effect of β-blocker use on functional decline. 28 At the end of the 90-day followup, participants were classified as alive without functional decline, having had functional decline documented in the first MDS assessment of that period, or having died without evidence of functional decline on the first MDS assessment. We used multiplicative and additive interaction terms to evaluate whether the effect of β-blockers on outcomes varied across participant characteristics. These characteristics included levels of baseline functional status, cognitive function, age, and presence or absence of an intensive care unit or cardiac care unit stay during the AMI hospitalization. The distribution of propensity scores was very similar for β-blocker users and nonusers within each subgroup, suggesting that stratifying patients into subgroups did not threaten covariate balance (eAppendix 4 in the Supplement).
The decision to exclude patients who died or were rehospitalized within 14 days after the AMI discharge has the potential to create selection bias. To evaluate this, we repeated our main analyses using inverse probability of selection weighting. 34, 35 This approach weighted participants according to their similarity to individuals who were excluded owing to death (n = 1859) or rehospitalization (n = 2444) in the first 14 days, thus estimating treatment effects as if these people had been included in the analysis. In another sensitivity analysis, we controlled for post-AMI use of other cardiovascular medications with multinomial logistic regression in our propensity-matched cohort. We also evaluated several alternate approaches to determine whether our results were stable across different analytic techniques. These approaches included stratifying by propensity score quintiles and deciles, controlling for propensity score as a covariate, using inverse probability of treatment weights, and performing time-dependent analyses. In each case, results were similar to our main approach (eAppendix 5 in the Supplement). We considered P < .05 to be statistically significant.
Results
Our initial cohort of 15 720 patients (11 140 new β-blocker users and 6767 nonusers. Before matching, β-blocker users were more likely to have been in an intensive care unit or a cardiac care unit during the hospital stay and to return to the nursing home on the Medicare Skilled Nursing Facility benefit care pathway and less likely to have a prior diagnosis of angina pectoris or unstable angina ( Table 1, Table 2 , and eAppendix 6 in the Supplement).
Propensity score matching yielded a cohort of 5496 new β-blocker users and an equal number of nonusers (Tables 1 and  2 ). Mean (SD) age was 84 (8) years; 7788 were women (70.9%); and 3204 were men (29.1%). The distribution of propensity scores was nearly identical between the matched groups (mean [SD] , 0.57 [0.11] in β-blocker users vs 0.57 [0.11] in nonusers; P = .63), and all but 2 variables had standardized mean differences of 0.03 or less (eAppendix 6 in the Supplement). This result is consistent with excellent covariate balance between groups.
31 Users and non- Within 3 months after hospital discharge, 1328 of 10 992 participants (12.1%) experienced functional decline; 2782 (25.3%) were rehospitalized; and 1541 (14.0%) died. Some patients experienced more than 1 outcome, such as rehospitalization and then death.
Users of β-blockers had a higher rate of functional decline than nonusers. In the first 90 days after AMI, the odds of functional decline were 1.14 (95% CI, 1.02-1.28) times greater in patients receiving β-blockers than in those not using β-blockers ( Table 3) . The number needed to treat to cause 1 patient to have functional decline was 52 (95% CI, 32-141). Results were similar using the more stringent threshold of a 4-point decline on the Morris ADL scale. Using this definition, 1165 subjects (10.6%) had functional decline, and β-blocker users were more likely to have a decline (odds ratio [OR], 1.16; 95% CI, 1.02-1.31).
Users of β-blockers were less likely than nonusers to die within 90 days of hospital discharge (hazard ratio [HR] , 0.74; 95% CI, 0.67-0.83) ( Figure 1A and Table 3 ). The number needed to treat to prevent 1 death was 26 (95% CI, 19-39). Use of β-blockers had no effect on time to rehospitalization (HR, 1.06; 95% CI, 0.98-1.14) ( Figure 1B and Table 3 ).
Use of β-blockers had no significant effect on a composite outcome of time to death, hospitalization, or functional decline (HR, 0.98; 95% CI, 0.94-1.03). Use of β-blockers showed a borderline small protective effect for a composite outcome that only included time to death or hospitalization (HR, 0.94; 95% CI, 0.88-1.00).
The effect of β-blocker use on death was similar across a variety of patient characteristics (Figure 2) . However, the effect of β-blocker use on functional decline varied according to patients' baseline cognitive and functional status (Figure 2 and eAppendix 7 in the Supplement). Among nursing home residents with moderate or severe cognitive deficits, β-blocker users were substantially more likely than nonusers to experience functional decline (OR, 1.34; 95% CI, 1.11-1.61), with a number needed to harm of 36 (95% CI, 24-76). In contrast, use of β-blockers did not increase the risk of functional decline in people with intact cognition or mild dementia (OR, 1.03; 95% CI 0.89-1.20; P = .03 for effect modification of treatment by cognition). Among residents with severe functional dependence at baseline, β-blocker users had greater risk of functional decline than did nonusers (OR, 1.32; 95% CI 1.10-1.59), with a number needed to harm of 25 (95% CI, 16-55). In contrast, β-blocker use did not increase the risk of functional decline in people in the best (OR, 0.99; 95% CI, 0.77-1.26) and intermediate (OR, 1.05; 95% CI, ) tertiles of baseline ADL functioning (P = .06 for effect modification of treatment by baseline functional status).
The main results were similar after applying inverse probability of selection weights, although the point estimate for the effect of β-blockers on functional decline was slightly attenuated, with 95% CIs crossing 1 (OR, 1.09; 95% CI, 0.96-1.24). Similar patterns held for results of subgroup analyses using selection weights (eAppendix 8 in the Supplement). Finally, results were similar after controlling for use of other cardiovascular medications in the post-AMI setting (eAppendix 5 in the Supplement).
Discussion
In this national study of older nursing home residents, using β-blockers after AMI resulted in a 26% relative reduction in 90-day mortality, with a number needed to treat of 26 to prevent 1 death. Similar levels of risk reduction were found across a wide variety of patient subgroups. However, β-blockers conferred a 14% relative increase in the odds of functional decline, with a number need to harm of 52 to cause 1 case of functional decline. This risk was particularly high for people with moderate or severe cognitive impairment or a high degree of functional dependence at baseline. In these groups, β-blockers increased the odds of functional decline by 32% to 34%, with a number needed to harm of 25 to 36. In contrast, nursing home residents with relatively pre- 
Research Original Investigation
Association of β-Blockers With Functional Outcomes After Acute Myocardial Infarction served cognitive and functional abilities did not appear to experience adverse functional consequences from receiving β-blockers. Our findings of mortality benefit are consistent with the results of other observational studies of β-blocker use among the old-old (aged ≥85 years), frail, and functionally impaired. [6] [7] [8] [9] 37, 38 Regarding harms, little is known about the effect of β-blockers on functional status. However, these agents increase the risk for fatigue (particularly first-generation agents such as propranolol hydrochloride) 12 and have been associated with increased rates of dizziness 39,40 and a decreased subjective sense of well-being, 41, 42 although no consistent effect has been found on rates of depression 12 or falls.
13,43
Our results confirm the suspicion of many physicians that poor cognitive and functional status increases the risk for medication-induced harms in older adults. However, they call into question the more general practice whereby older adults are less likely to receive guideline-recommended medications after AMI regardless of their mental or physical abilities. 7, 10, 11, 44 For nursing home residents with intact cognition or mild dementia and in those with nonsevere levels of functional dependency, we found substantial mortality benefit and no functional harms. Therefore, treatment is appropriate for most such patients. In contrast, for nursing home residents with extensive functional dependency or moderate to severe dementia (roughly corresponding to a Folstein Mini-Mental State Examination score of ≤14 of 30 points), 29 resolving the tradeoff between reduced mortality and increased risk for functional decline will depend on patient preferences, as expressed directly or through surrogate decision makers. 45, 46 For cognitively or functionally impaired nursing home residents who are more concerned about functional decline than death, avoiding treatment may be preferable. This is a large population; more than half of nursing home residents have high levels of functional dependence, and twothirds have moderate or severe cognitive impairment.
47
Limitations
Because this study is observational, we cannot rule out the possibility of confounding. However, several factors support the robustness of our findings. We obtained an excellent balance of baseline covariates across treatment groups and consistent results using several alternate analytic approaches. Moreover, younger and healthier patients are more likely to receive secondary prevention medications after AMI. 7, 10, 11, 44, 48 This likelihood would bias results toward better outcomes in β-blocker users. Instead, functional outcomes were in the opposite direction of this expected bias. Cointerventions constitute another important consideration. People who used β-blockers after AMI were also more likely to receive statins and angiotensin-converting enzyme inhibitors in the post-AMI period. Controlling for these differences slightly attenuated the observed associations between β-blocker use and our outcomes of interest, although the overall pattern remained.
To enable robust assessment of β-blocker exposure, we excluded patients who died or were rehospitalized within the first 14 days of hospital discharge. This exclusion prevented us from evaluating the effect of β-blockers on outcomes during this period. Thus, our results should be interpreted as providing evidence about the effect of β-blocker use on outcomes starting 14 days after discharge, among people who had survived and remained in the nursing home until then. In addition, these exclusions could induce selection bias. 34, 35 However, although our sensitivity analyses were consistent with the possibility of mild selection bias, we found little evidence of bias sufficiently large to invalidate our overall findings. 
Conclusions
Use of β-blockers after AMI resulted in substantial reductions in mortality among older nursing home residents. At the same time, use of these agents resulted in worse functional outcomes among nursing home residents with substantial cognitive or functional deficits. In this highly vulnerable group, understanding the importance that individual patients place on avoiding death and on avoiding functional decline will be critical to guiding decision making about use of these medications. 
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LESS IS MORE
Guideline-Based Prescribing in Frail Elderly Patients
Jennifer Tjia, MD, MSCE; Kate Lapane, PhD
In this issue of JAMA Internal Medicine, Steinman and colleagues 1 report on their carefully designed observational study of the comparative benefits and harms of β-blocker use for acute myocardial infarction (AMI) in adults 85 years or older-a population for whom no evidence from randomized clinical trials exists. They found that, within 3 months of hospital discharge after AMI, 12.1% of their study population experienced functional decline, 25.3% were rehospitalized, and 14.1% died. Use of β-blockers decreased the odds of death regardless of functional status. This should be good news. Guideline-based medications for AMI have been underused in older adults. The study's confirmation of the survival benefit for frail elders will likely spur an increase in β-blocker prescribing for older adults with multiple comorbidities.
However, this well-executed study reveals a more complex phenomenon. Use of β-blockers increased the risk for functional decline among the cognitively and functionally impaired. Steinman et al 1 report that, among elders with functional or cognitive impairment, the number needed to harm is similar to the number needed to treat to prevent 1 death. This journal's "Less is More" series and the American Board of Internal Medicine Foundation's Choosing Wisely campaign highlight the need to curtail the use of nonbeneficial and potentially harmful medications, tests, and treatments. Thus, these findings must give us pause. Despite some individuals wanting to live forever, in reality, many older adults reach the point when quality of life is more important than extension of life. The study by Steinman et al 1 is important because the primary outcome was functional decline and not death or hospital readmission. The authors confirmed that the practice of avoiding prescription of β-blockers in frail and highly vulnerable elders with functional impairment is reasonable. Steinman et al 1 extend that knowledge 1 step further. They shed some light on where the tipping point is. In the nursing home population, this point appears to be at the level of moderate cognitive impairment (ie, having short-term memory loss and a moderately impaired ability for decision making or an inability to make their needs understood) or severe functional impairment (ie, extensive assistance or total dependence for most, if not all, activity of daily living needs, including dressing, personal hygiene, toileting, ambulation, transferring, bed mobility, and eating). The most common causes of exclusion were failure to return to a nursing home and remain there for 14 days, and lack of Part D data (e.g. due to lack of Part D insurance coverage) in the post hospital period. Nursing home care pathways and medication ascertainment: implications for methods.
References
In the immediate post hospital period, long stay nursing home patients who return to their nursing homes typically enter one of two care pathways. Some patients immediately re enter the standard long term care (LTC) pathway, in which Medicare Part D pays for medications, and other sources (typically Medicaid, private long term care insurance, or self pay) fund other costs. Patients with short term rehabilitation potential or skilled nursing needs may be covered in the short term by the Medicare Part A funded Skilled Nursing Facility (SNF) benefit. Bundled payments under the SNF benefit include medication purchases. After a short period (typically about 1 month, and at most 100 days), long stay patients transition back to the long term care pathway, in which Medicare Part D once again covers drug purchases. Note that both SNF benefit care and long term care typically occur in the same facility; the patient stays in his or her usual bed regardless, but the payment mechanism and services provided differ.
Because we were unable to directly observe beta blocker prescriptions using Part D claims while patients were on the Medicare SNF benefit, we conducted a validation study using enriched pharmacy data from a national nursing home chain (Manor Care) to evaluate the relationship between beta blocker use that occurred during the SNF funded care and beta blocker use that occurred after those patients had transitioned back to long term care. In this validation study, over 94% of nursing home residents who used beta blockers after transitioning to long term care had also used these drugs during their SNF care. To evaluate comparability of Manor Care residents to residents of other facilities in our main cohort, we compared characteristics of Manor Care vs. non Manor Care subjects (Table A1 , below). Most characteristics were similar. Together, this suggests it is reasonable to use beta blocker use in the post SNF phase to evaluate whether patients were using beta blockers while covered under the Medicare SNF benefit.
We chose a 30 day grace period for evaluating beta blocker use after resumption of Part D coverage because this allows for delays in ordering these medications through Part D. This includes time for patients to utilize the limited supply of medications that an acute care hospital may send with the patient upon their return to the nursing home before a new supply is ordered, or for the patient to utilize a supply of drug that was purchased while on SNF benefit care and is still available to use even after transitioning to long term care. In nursing homes, the maximum allowable days supply for a medication purchase is 30 days. 
Assessing Functional Decline
We used the validated 28 point Morris Activity of Daily Living (ADL) scale, derived from MDS 2.0 data, to evaluate functional decline. Periodic MDS assessments by a trained assessor, typically a member of the nursing home staff, are mandated for all patients in Medicare or Medicaid certified nursing homes. They occur on a set schedule, occurring a minimum of every 3 months, and more often for patients with a substantial recent change in clinical status and those receiving care under the SNF benefit. During assessments, independence in each of 7 ADLs is evaluated on scale from 0 (independent) to 4 (total dependence). These are summed to create a 28 point score. To evaluate functional decline, we subtracted the baseline ADL assessment (i.e. the most recent assessment prior to the index MI) from the first follow up assessment between 15 114 days after discharge from the AMI hospitalization. We did not evaluate MDS assessments in days 0 14 following hospitalization to be consistent with our exclusion criteria, which excluded people who died or were rehospitalized during this period. (This is because it is difficult to reliably ascertain beta blocker exposure in the post hospitalization period among people who leave the nursing home shortly after returning to it). We also added a grace period of 2 weeks at the end of the 90 day post hospital period to capture additional MDS assessments (i.e., days 91 114). We added this grace period because MDS assessments are conducted only intermittently, and reflect changes in clinical status that have already occurred prior to the assessment. Moreover, they are mandated to occur at least once per 90 days, thus giving a full 90 days of available followup time after day 15. We defined a decline in 3 points or greater to be a meaningful functional decline. We chose this threshold because it represents a meaningful drop in functional decline and is common enough to be present in a reasonable proportion of subjects.
Censoring in Outcomes Analyses:
We did not censor for any events other than outcome and end of follow up period. This is because we had complete ascertainment of death regardless of residence and Medicare status, and for the outcome of hospitalization is it extremely uncommon for older adults to be disenrolled from Medicare. For the functional status outcome, leaving the nursing home could affect outcome ascertainment. We thus explored several potential approaches to censoring for this outcome, but all returned essentially identical results -in large part because only 3% of subjects in our cohort had zero MDS assessments of functional status in the first 90 days after hospitalization.
American Medical Association All rights reserved Part D Binary indicator of presence of cox 2 selective non steroidal anti inflammatory drug (e.g. celecoxib) in 1 yr prior to index MI d_Vasodilator Part D Binary indicator of presence of direct acting vasodilator drug (e.g. hydralazine) in 1 yr prior to index MI * LOCF = last observation carried forward. * Data from OSCAR were obtained using the most recent OSCAR assessment prior to a subject's index hospitalization for AMI.
eAppendix 3. Companion Study Using Department of Veterans Affairs Data
Because MDS and Medicare claims files do not contain all clinically relevant data, there is the possibility of unmeasured confounding not captured in our propensity scores. To address this, we assembled a cohort of 162 older adults in Department of Veterans Affairs nursing homes who met inclusion criteria. We then used national VA and VA/MDS data to recreate propensity scores in this cohort, using parameter estimates from our main (Medicare) propensity score model. In these models we assessed beta blocker use within the first week after hospital discharge (yes/no), as there were very few people who were not dispensed a beta blocker in the first 7 days who later went on to use the drug over the following month. We then added evaluated how addition of several variables not available in our main study, including vital signs (pulse, systolic and diastolic blood pressure, body mass index), key laboratory tests (peak troponin, estimated glomerular filtration rate, serum albumin), and measures of left ventricular ejection fraction affected the relationship between beta blocker use and each of our outcomes of interest after controlling for propensity score. We measured vital signs and labs (except peak troponin) based on the first vital sign or lab recorded on the day the patient returned from the hospital to the nursing home, or the most recent prior if a given vital sign or lab was not available on that day. We measured peak troponin based on the largest value of Troponin T or Troponin I measured during the hospital stay. We assessed left ventricular ejection fraction using a natural language processing algorithm developed in VA's VINCI platform that incorporates data from studies such as echocardiography and nuclear medicine reports and free text notes.
Characteristics of the VA cohort are shown in Table A3 1. The biggest difference between the VA cohort and main (ie. Medicare propensity matched) cohort was the predominance of men in the VA cohort, consistent with the overall sex distribution among older VA patients. Mean age, selected comorbid conditions, and median ADL score were generally similar between the two groups, although fewer patients in the VA cohort were admitted to ICU compared with the Medicare cohort.
As shown in Table A3 2, inclusion of additional variables only available in VA data did not significantly change the relationship between beta blocker use and our outcomes of interest. This suggests that our inability to measure vital signs, laboratory test results, and possibly measures of left ventricular function in our main cohort did not create a major bias in our results. However, given the small sample size and resulting wide confidence intervals, and certain differences between the VA and Medicare cohorts (mainly the distribution of men and women, and rates of ICU utilization), we are unable to rule out non major effects. Table A3 2 shows results of these analyses, which we modeled in 2 ways. The first row of results shows the odds ratio for the association between beta blocker use and the outcome of interest after controlling for the original propensity score ("old PS"). This original propensity score was created using parameter estimates from our main (Medicare) propensity score models. Subsequent rows under the heading "Method 1" show the odds ratio for the association between beta blockers and the outcome of interest after adding the new variable as an additional predictor in the model (e.g. outcome = beta blocker + propensity score + new variable ). Rows under the heading "Method 2" show the odds ratio for the association between beta blockers and the outcome of interest after controlling for a new propensity score that was created based on the original propensity score and the additional variables of interest. In both methods, note the wide confidence intervals. Also note that results from the left ventricular ejection fraction data had high degrees of missingness, since many patients did not have any left ventricular ejection fraction measured in VA health care settings during the assessment period. As a result, effect estimates for the left ventricular ejection fraction analyses are not reliable. (63) 7 (6) 39 (32) 22 (58) 1 (3) 15 (37) Chronic conditions Diabetes Heart failure COPD Depression 57 (46) 60 (48) 50 (40) 18 (15) 15 (40) 11 (29) 15 ( 
eAppendix 4. Propensity Score Balance Within and Across Subgroups
We evaluated the effect of beta blockers on our outcomes of interest across subgroups with different levels of baseline functional status, baseline cognitive status, age, and presence or absence of a stay in an intensive care unit (ICU) or coronary care unit (CCU) during the index hospitalization.
Within each subgroup, propensity scores were very similar between beta blocker users vs. non users (see table below). Mean propensity scores were also very similar for patients with different levels of functional status, cognitive performance, and age. In contrast, patients who had stayed in an ICU or CCU had higher mean propensity score than patients without any ICU or CCU stay (mean propensity score 0.592 vs. 0.530).
To test whether differences in the propensity score distribution between people with or without an ICU/CCU stay would affect our subgroup analyses, we ran our effect modification models for the impact of ICU/CCU stay both with and without including the propensity score as a covariate. Results of both models were almost identical, so in the paper we present the simpler (e.g. not adjusted for propensity score) results. To evaluate the stability of our results using different modeling techniques, we conducted our analyses using several alternate analytic approaches. To assess comparability of results from multinomial models and Cox proportional hazards models, we applied both methods to modeling the impact of beta blocker use on death (Table A5 1 ). We also conducted our key analyses stratifying by propensity score quintile and decile in unmatched cohorts (Table A5 2), controlling for propensity score as a continuous covariate (Table A5 3), and using inverse probability of treatment weight (IPTW) based approaches (Table A5 4 ). In each case, results were similar to our main approach.
When we performed IPTW based analyses in the original (full) cohort, the effect estimate for functional decline was attenuated with 95% confidence intervals crossing 1. However, as subjects at the margins of the propensity score distribution were trimmed -thus isolating individuals for whom there is clinical equipoise the effect estimate converged to a value close to our main analyses (Table A5 4 ).
We considered the risk of immortal time bias in our study to be low. This is because more than 90% of nursing home residents who used a beta blocker after AMI started it within the first 14 days after hospitalization, and we excluded subjects who had died or were re hospitalized within this time frame. To confirm this, we compared time fixed vs. immortal time corrected (i.e., time dependent) effect estimates for a subset of subjects where they could be meaningfully compared. Results were very similar in the 2 approaches (Table A5 5 ).
We also explored the possibility of analyzing our data using instrumental variable approaches. To do this, we evaluated whether hospital or nursing home facility could be used as an instrument, e.g. by defining the percentage of patients treated at the institution who received a beta blocker. However, the number of patients per institution was small, such that estimates of facility level treatment preference would be unstable. For example, the median number of patients per hospital was 7. We then tested a reduced model that included only hospitals with at least 5 patients represented in the dataset, and included a random intercept for hospital. On average, hospital accounted for only 3.5% of variation in beta blocker prescribing in the reduced model, suggesting it is a weak instrument. Given these limitations, we elected not to use facility treatment preference/pattern as an instrumental variable.
Finally, we repeated our main analyses using multinomial logistic regression to control for differences in use of other cardiovascular medications after AMI between beta blocker users and non users (Table A5 6 ). This included use of statins, ACE inhibitors, and angiotensin receptor blockers, whose use was ascertained using the same methods we used to ascertain beta blocker use after AMI. We also explored evaluating differences in antiplatelet agents (aspirin and clopidogrel), but results of these analyses suggested we were not completely capturing aspirin use, which was not unexpected since it is an inexpensive, over the counter medication that may be dispensed as ward stock and thus not captured in Part D claims. As shown in Table A5 6, controlling for these other medications slightly attenuated the observed associations between use of beta blockers and functional decline and death, but the overall pattern of effects remained the same. Rather than match on the propensity score, these models adjust for the propensity score as categorical strata. In these analyses, we trimmed 1% in each tail of the distribution of propensity score to discard residents in each exposure with propensity scores outside the range of common support, leaving 15,397 subjects available for analysis. Rather than match on the propensity score, these models adjust for the propensity score as a continuous covariate. In these analyses, we trimmed 1% in each tail of the distribution of propensity score to discard residents in each exposure with propensity scores outside the range of common support, leaving 15,397 subjects available for analysis. Table A5 4. Analyses using inverse probability of treatment weights
Adjustment strategy
The mean (SD) IPTW was 0.999 (0.320), with range of 0.471 to 5.633. This suggests IPTW approaches may be appropriately applied to these data.
We performed our first set of IPTW analyses on the full cohort of 15,712 subjects (e.g. without any trimming). We then repeated the analyses after progressively trimming subjects at the margins of the propensity score distribution, so as to isolate individuals for whom there is clinical equipoise. As the tails were further trimmed, the effect estimates moved slightly farther away from unity. We considered the possibility of immortal time bias. In our study, immortal time consists of the time between nursing home admission and the first dispensing of a beta blocker. To evaluate this, we performed a time dependent (i.e., time varying) analysis of time to death by beta blocker exposure status. We focused on the subset of 3,231 subjects in our propensity score matched cohort who returned from hospital to nursing home on the long term care (LTC) pathway, and thus had no period where new prescriptions were unobservable (because Medicare Part D resumed coverage immediately upon return to the nursing home).
The following table contrasts results from our main analytic approach in the LTC group vs. results obtained using time varying mortality estimates that corrected for immortal time bias. The similarity of the two estimates suggests that any immortal time bias is small. This appendix contains 3 figures that illustrate covariate balance and the distribution of propensity scores in beta blocker treated and -untreated subjects before and after matching. Figure A6 A. Standardized mean difference in subject characteristics among beta blocker users vs. non users, before and after propensity score based matching
Cohort
Prior to propensity score matching, the biggest differences between beta blocker users and non users were that users were less likely to have a prior diagnosis of angina pectoris (standardized mean difference [SMD} 0.22) and unstable angina (SMD 0.11), less likely to have used loop diuretics (SMD 0.11), nitrates (SMD 0.10), and vasodilators (SMD 0.10) in the year prior to hospitalization, and were more likely to have been in an ICU or CCU during the AMI hospital stay (SMD 0.14) and to return to the nursing home on the SNF benefit care pathway (SMD 0.11). Lower use of beta blockers in nursing home residents with a history of angina pectoris and unstable angina may reflect the new user nature of our study design: since these conditions are symptomatic manifestations of ischemic heart disease, patients with these conditions may already have already been considered for and declined beta blocker use prior to the index AMI.
After propensity score matching, the largest residual differences were that beta blocker users were more likely to have pain at the pre hospital baseline (SMD 0.05) and less likely to have used a class II antiarrhythmic in the previous year (SMD 0.06). All other variables had post match standardized mean differences of 0.03 or less. This is consistent with excellent covariate balance; which is generally considered robust for SMDs of 0.10 or less (Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity score matched samples. 2009; 28(25) : 3083 107) In the figure, blue X's represent the absolute SMD between groups prior to propensity score matching, and the red circles represent the absolute SMD after matching. The dashed line at SMD 0.10 represents a commonly used threshold below which post matching covariate balance is considered robust. To evaluate whether the exclusion criterion that required 14 days of death and hospital free survival after the AMI discharge could have introduced selection bias, we repeated our main analyses using inverse probability of selection weighting. This approach weights subjects according to their similarity to individuals who were excluded due to death or re hospitalization in the first 14 days, thus estimating treatment effects as if these people had been included in the analysis. We did this by calculating a propensity score for each subject who died or was rehospitalized in the first 14 days after hospital discharge, and using these scores as inverse probability of selection weights.
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eAppendix 7. Detailed results from subgroup analyses, including number needed to treat (NNT) and number needed to harm (NNH)
Using this approach, the mean (SD) weight was 0.998 (0.356), with a minimum weight of 0.07 and a maximum weight of 17.18.
The following table shows the effect estimate for the impact of beta blockers on mortality and functional decline using the original approach, and using the selection weighted approach. To enhance comparability, in these analysis mortality is estimated using a multinomial logit model, not the Cox proportional hazards model used for the main analysis (however, the two methods produce very similar results). All analyses were conducted using the propensity matched cohort of beta blocker users and non users. Weights were stabilized, and there were no zero cells.
While inverse probability of selection weights are typically applied to non matched rather than matched samples, applying this method to a matched sample is conceptually analogous to propensity score matching in a complex survey, where inverse probability weights are used to standardize the population to the target (see Dugoff EH et al.
Generalizing observational study results: applying propensity score methods to complex surveys. Health Serv Res. 2014 Feb; 49(1) :284 303). The following tables show results stratified by patient characteristics of particular interest: baseline independence in ADLs, and baseline cognition (as measured by CPS score). 
